S&P 500 jumps to record ahead of key Fed decision on interest rates: Live updates

S&P 500 jumps to record ahead of key Fed decision on interest rates: Live updates


Traders work on the floor of the New York Stock Exchange.

Brendan Mcdermid | Reuters

The S&P 500 hit a record high Tuesday as the market awaited the Federal Reserve’s key interest rate cut decision.

The broad market index was last up 0.4% at the 5,650 level, after earlier touching a new record high of 5,670.81. The Nasdaq Composite gained 0.7%, and the Dow Jones Industrial Average advanced 103 points, or 0.3%. The 30-stock Dow also reached a fresh all-time high.

Stock Chart IconStock chart icon

hide content

S&P 500 in 2024

The S&P 500’s move to an all-time high comes during a historically tough period for the market. September has been the worst month for the benchmark over the last 10 years, averaging a 1.3% monthly loss, according to FactSet data.

Traders also overcame late-summer headwinds stemming from concerns over the health of the U.S. economy. Disappointing jobs and manufacturing data in August sparked a large one-day sell-off. However, equities were able to rebound thanks to more constructive data releases and expectations of the Fed lowering rates.

Wall Street is on standby for the Fed’s long-anticipated rate cut Wednesday afternoon, a move that could help boost earnings growth for companies following a backdrop of steep borrowing costs and high inflation. The Fed first embarked on its aggressive hiking campaign in March 2022.

The latest retail sales data indicated solid consumer health. Retail sales rose 0.1% in August versus economists’ estimates for a 0.2% decline, according to Dow Jones. Excluding autos, the number also came in at a 0.1% increase, which slightly missed the 0.2% consensus forecast.

While investors expect a cut Wednesday, the market is divided on the size of the potential reduction. Traders are currently pricing in a 59% chance that the central bank eases rates by 50 basis points, according to CME Group’s Fed Watch tool. That’s up from a roughly 47% chance Friday, but slightly lower from the 67% earlier forecasted on Tuesday. One basis point equals 0.01%.

A steeper rate cut may spark concerns about the health of the economy, according to some investors.

“A 50 basis point cut may further imply a downgrade of the Fed’s view on the labor market — that would be more of a concerning sign,” said Adam Turnquist, chief technical strategist at LPL Financial. “I think there’s going to be a pretty big deviation between what the market is expecting, and what the Fed is going to project.”

Microsoft rose 1% after the tech giant hiked its quarterly dividend by 10.7% to 83 cents per share. The company also approved a $60 billion buyback program. Intel shares jumped more than 6% after the company said it plans to make its foundry business a subsidiary. The Biden administration also awarded the company up to $3 billion in funding through the Chips Act.



Source

Google joins Microsoft in telling users Anthropic is still available outside defense projects
World

Google joins Microsoft in telling users Anthropic is still available outside defense projects

Google CEO Sundar Pichai gestures to the crowd during Google’s annual I/O developers conference in Mountain View, California, on May 20, 2025. David Paul Morris | Bloomberg | Getty Images Google said it will continue offering Anthropic’s artificial intelligence technology for clients, excluding for defense work, a day after Microsoft issued a similar statement to […]

Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
World

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]

Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
World

Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’

Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]

Read More